Battling chronic myeloid leukemia in a resource-constrained country: A case of public-private partnerships

Author:

Tariq RabbiaORCID,Fatima Irtebaat,Shahid Muhammad H.,Tariq Samiuddin,Niaz Faizan,Hussain Syed M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference16 articles.

1. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience;Kantarjian;Blood,2012

2. Clinical and hematological features of 335 patients of chronic myelogenous leukemia diagnosed at single centre in northern Pakistan;Bhatti;Clin Med. Blood Dis,2012

3. World Chronic Myeloid Leukemia Day: Leukemia common among younger Pakistanis. Express Tribune Web Archives 26 September 2013:5. Available at: https://tribune.com.pk/story/609805/world-chronic-myeloid-leukemia-day-leukemia-common-among-younger-pakistanis. Accessed June 29, 2022.

4. Response and adverse effects of nilotinib in imatinib-resistant chronic myeloid leukemia patients: data from a developing country;Hussain;Clinical therapeutics,2015

5. Yusufzai Mushtaq. KP govt to continue providing free treatment to poor cancer patients. The News International. 23 September 2019. Available at: https://www.thenews.com.pk/print/530827-kp-govt-to-continue-providing-free-treatment-to-poor-cancer-patients. Accessed July 3, 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3